Product Description
For locally advanced or metastatic soft tissue sarcoma (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00017446)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Herbert Irving Comprehensive Cancer Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Sarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CDR0000068689 | P2 |
Unknown status |
Sarcoma |
None |